ArticleThe oncologist2021

First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.

Shen Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.